Article Contents ::
- 1 The Brand Name MESNA Has Generic Salt :: MESNA
- 2 MESNA Is From Company Cipla Priced :: Rs. 90
- 3 MESNA have MESNA is comes under Sub class Cytoprotectives of Main Class Anti Neoplastic Agents
- 4 Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Cytoprotectives
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name MESNA Has Generic Salt :: MESNA
MESNA Is From Company Cipla Priced :: Rs. 90
MESNA have MESNA is comes under Sub class Cytoprotectives of Main Class Anti Neoplastic Agents
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Cytoprotectives
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| MESNA | INJ | Rs. 90 | 2ML AMP. |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 2ML AMP. |
| MESNA | Cipla | 200MG/2ML | 2ML AMP. | Rs. 90 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Cipla :: MESNA | MESNA | Anti Neoplastic Agents | Cytoprotectives |
Indications for Drugs ::
Urothelial toxicity
Drug Dose ::
Intravenous Prophylaxis against urothelial toxicity Adult: Refer to individual and local protocol. Dose calculated according to cytotoxic dose. Normally given at a dose >cytotoxic dose. Duration of treatment should be as long as cytotoxic treatment; plus the time it takes for concentration of antineoplastic metabolites in urine to fall. Administered either by short (15-30 minutes) or continuous (24 hr) infusion.
Contraindication ::
Hypersensitivity to thiol-containing compounds.
Drug Precautions ::
Protective effect applies only to the urinary tract; pregnancy, lactation. Patients with auto-immune disorders. IV formulation may contain benzyl alcohol as a preservative; avoid in neonates or infants. Instruct patients to seek medical attention if discolouration of urine occurs. During treatment, monitor urine for erythrocytes and haematuria. Maintain adequate hydration in all patients. Patients who vomit within 2 hr of oral dose should repeat dose or receive IV dose.
Drug Side Effects ::
Nausea, vomiting, colic, diarrhoea, anorexia, dyspepsia, unpleasant taste, constipation; headache, malaise, fatigue, depression, irritability, somnolence, hyperaesthesia, dizziness, confusion; rash, pruritus, generalised urticaria, alopecia, inj site reactions, flushing; leucopenia, thrombocytopenia, anaemia, granulocytopenia, chest pain, oedema (peripheral, facial and periorbital), hypotension, tachycardia, hypertension, increased heart rate, ST-segment elevation; dyspnoea, coughing, pneumonia, tachypnea; fever; hypocalcaemia; increased sweating; back pain, limb pain, myalgia; increased hepatic enzyme concentrations; pharyngitis; ulceration of mucous membranes. In patients receiving oral and/or IV mesna and were specifically not treated with concurrent cytotoxic therapy: flatulence; rhinitis; rigors; back pain; rash; conjunctivitis; arthralgia. Inhalation: bronchospasm. Potentially Fatal: May cause haemorrhagic cystitis, systemic anaphylactic reactions.
Pregnancy category ::
2
Drug Mode of Action ::
Mesna is used to prevent urothelial toxicity associated with oxazaphosphorine, ifosfamide or cyclophosphamide. It acts in the kidney; reacting with thiol groups of urotoxic metabolites (e.g. acrolein) of ifosfamide and cyclophosphamide. It is used as a mucolytic in the management of some respiratory tract conditions e.g. cystic fibrosis where other mucolytics have failed. It acts by reducing the viscosity of pulmonary secretions; the drug’s free sulfhydryl group is thought to reduce disulfide linkages of mucoproteins.
Drug Interactions ::
Mesna is incompatible in vitro with cisplatin and nitrogen mustard.
